Comparison of kidney cancer symptoms and quality of life (QoL) in renal cell cancer (RCC) patients (pts) receiving sorafenib vs interferon-α (IFN)

9603 Background: Sorafenib, an oral multi-kinase inhibitor with anti-angiogenic and anti-proliferative activity, inhibits VEGFR, PDGFR, c-Kit, Flt-3, RET, and Raf/MEK/ERK. Sorafenib has demonstrated activity in multiple tumor types including BC, HCC, melanoma, NSCLC, and RCC. Methods: The phase II trial randomized 189 pts with advanced RCC who had received no prior systemic therapy to continuous oral sorafenib 400 mg bid or IFN 9 million units tiw. A second trial phase allowed pts to cross over at progression to sorafenib 400 mg bid from the IFN arm or escalate to sorafenib 600 mg bid if they were on the sorafenib arm. Here we report the results of the treatment effect of sorafenib vs IFN on pt reported outcomes (PRO) from the first phase of this trial of pts with advanced RCC receiving first- line therapy. Kidney cancer symptoms were measured using a 15-item functional assessment of Therapy-Kidney Symptom Index (FKSI). QoL was measured using the Functional Assessment of Therapy-Biologic Response Modifier...